These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 31493351)

  • 1. Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression.
    Xu Q; Long Q; Zhu D; Fu D; Zhang B; Han L; Qian M; Guo J; Xu J; Cao L; Chin YE; Coppé JP; Lam EW; Campisi J; Sun Y
    Aging Cell; 2019 Dec; 18(6):e13027. PubMed ID: 31493351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amphiregulin mediates non-cell-autonomous effect of senescence on reprogramming.
    von Joest M; Chen C; Douché T; Chantrel J; Chiche A; Gianetto QG; Matondo M; Li H
    Cell Rep; 2022 Jul; 40(2):111074. PubMed ID: 35830812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction to "Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression".
    Aging Cell; 2024 Jul; 23(7):e14248. PubMed ID: 38873935
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity.
    Tao Z; Ruan H; Sun L; Kuang D; Song Y; Wang Q; Wang T; Hao Y; Chen K
    Cancer Immunol Res; 2019 Jul; 7(7):1135-1147. PubMed ID: 31113805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the immunosuppressive PD-1/PD-L1 checkpoint pathway in the aging process and age-related diseases.
    Salminen A
    J Mol Med (Berl); 2024 Jun; 102(6):733-750. PubMed ID: 38600305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
    Liu H; Shen J; Lu K
    Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.
    Guan X; LaPak KM; Hennessey RC; Yu CY; Shakya R; Zhang J; Burd CE
    Mol Cancer Res; 2017 Mar; 15(3):237-249. PubMed ID: 28039358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis.
    Raimondo S; Saieva L; Vicario E; Pucci M; Toscani D; Manno M; Raccosta S; Giuliani N; Alessandro R
    J Hematol Oncol; 2019 Jan; 12(1):2. PubMed ID: 30621731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.
    Böttcher M; Bruns H; Völkl S; Lu J; Chartomatsidou E; Papakonstantinou N; Mentz K; Büttner-Herold M; Zenz T; Herling M; Huber W; Ghia P; Stamatopoulos K; Mackensen A; Mougiakakos D
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Senescent cells re-engineered to express soluble programmed death receptor-1 for inhibiting programmed death receptor-1/programmed death ligand-1 as a vaccination approach against breast cancer.
    Chen Z; Hu K; Feng L; Su R; Lai N; Yang Z; Kang S
    Cancer Sci; 2018 Jun; 109(6):1753-1763. PubMed ID: 29675979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Senescent stromal cell-induced divergence and therapeutic resistance in T cell acute lymphoblastic leukemia/lymphoma.
    Habiel DM; Krepostman N; Lilly M; Cavassani K; Coelho AL; Shibata T; Elenitoba-Johnson K; Hogaboam CM
    Oncotarget; 2016 Dec; 7(50):83514-83529. PubMed ID: 27835864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting senescent cells to reshape the tumor microenvironment and improve anticancer efficacy.
    Jiang B; Zhang W; Zhang X; Sun Y
    Semin Cancer Biol; 2024 Jun; 101():58-73. PubMed ID: 38810814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
    Hack SP; Zhu AX; Wang Y
    Front Immunol; 2020; 11():598877. PubMed ID: 33250900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.
    Oliveras-Ferraros C; Cufí S; Queralt B; Vazquez-Martin A; Martin-Castillo B; de Llorens R; Bosch-Barrera J; Brunet J; Menendez JA
    Br J Cancer; 2012 Apr; 106(8):1406-14. PubMed ID: 22491422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
    Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
    Front Immunol; 2021; 12():799455. PubMed ID: 35069581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amphiregulin in Cancer: New Insights for Translational Medicine.
    Xu Q; Chiao P; Sun Y
    Trends Cancer; 2016 Mar; 2(3):111-113. PubMed ID: 28741529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapeutic HCW9218 augments anti-tumor activity of chemotherapy via NK cell-mediated reduction of therapy-induced senescent cells.
    Chaturvedi P; George V; Shrestha N; Wang M; Dee MJ; Zhu X; Liu B; Egan J; D'Eramo F; Spanoudis C; Gallo V; Echeverri C; You L; Kong L; Fang B; Jeng EK; Rhode PR; Wong HC
    Mol Ther; 2022 Mar; 30(3):1171-1187. PubMed ID: 35051615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The up-regulation of PD-L1 during boningmycin-induced senescence in human cancer cells depends on the activation of the JAK/STAT signaling pathway mediated by SASP.
    Chen Y; Shen J; Zhao X; He Q; Zhang J
    Immunol Cell Biol; 2024 Oct; 102(9):847-859. PubMed ID: 39044372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
    Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.